Twist Bioscience (NASDAQ:TWST) PT Raised to $56.00 at Evercore ISI

Twist Bioscience (NASDAQ:TWST) had its price objective boosted by analysts at Evercore ISI from $52.00 to $56.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Evercore ISI’s price target indicates a potential upside of 31.18% from the company’s previous close.

Several other research firms also recently weighed in on TWST. TD Cowen lifted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Robert W. Baird upped their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Finally, Barclays reduced their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

Twist Bioscience Price Performance

Shares of TWST traded down $2.49 during mid-day trading on Tuesday, hitting $42.69. The stock had a trading volume of 380,261 shares, compared to its average volume of 990,342. The firm has a market cap of $2.50 billion, a P/E ratio of -12.72 and a beta of 1.76. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $60.90. The business has a fifty day moving average price of $46.09 and a 200-day moving average price of $43.50.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.01) EPS. As a group, research analysts expect that Twist Bioscience will post -3.13 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 5,139 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the completion of the sale, the chief executive officer now directly owns 499,593 shares of the company’s stock, valued at $19,948,748.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now directly owns 499,593 shares of the company’s stock, valued at approximately $19,948,748.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Patrick John Finn sold 2,207 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the transaction, the chief operating officer now directly owns 171,212 shares in the company, valued at $9,694,023.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,348 shares of company stock worth $673,091. 3.92% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after buying an additional 613,057 shares during the last quarter. Fred Alger Management LLC increased its position in shares of Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the period. Victory Capital Management Inc. boosted its stake in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after acquiring an additional 300,891 shares in the last quarter. Norges Bank acquired a new stake in shares of Twist Bioscience during the fourth quarter worth $10,766,000. Finally, Farallon Capital Management LLC purchased a new position in shares of Twist Bioscience during the second quarter worth $9,462,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.